toxylact

The first professional lActological database in the word

Mazindol (ATC A08AA05): Toxicological and Lactation Monograph

ATC class and general pharmacology

ATC code A08AA05 corresponds to mazindol, a centrally acting anti-obesity medicine classified within ATC group A08A, anti-obesity preparations, excluding diet products, and subgroup A08AA, centrally acting anti-obesity products. Mazindol is an anorectic agent historically used as a short-term adjunct to dietary, behavioural, and physical-activity interventions for obesity. It should not be considered a substitute for comprehensive long-term obesity care.kegg+1

Mazindol is a tricyclic imidazo-isoindole derivative with pharmacological properties that overlap partly with amphetamine-like anorectic agents, although its chemical structure and mechanism are distinct. Its principal therapeutic effect is appetite suppression through central nervous system activity. Available pharmacological data indicate inhibition of monoamine transporters, including the norepinephrine transporter (NET/SLC6A2), dopamine transporter (DAT/SLC6A3), and serotonin transporter (SERT/SLC6A4). By reducing neuronal reuptake of norepinephrine, dopamine, and serotonin, mazindol enhances monoaminergic neurotransmission in neural circuits regulating appetite, arousal, reward, and autonomic function.kegg

The anorectic effect is associated with central stimulation and may be accompanied by reduced food intake, insomnia, nervousness, autonomic activation, and increased heart rate. Tolerance to appetite-suppressant effects may develop after several weeks. Dose escalation in response to declining efficacy is inappropriate because it increases toxicological risk without reliably restoring sustainable weight loss.pdf.hres

Following oral administration, mazindol is absorbed relatively rapidly. In the cited product monograph, measurable blood concentrations occurred approximately 30 minutes after a single 1–2 mg dose, peak plasma concentrations were reached at a mean of 3.6 hours, plasma protein binding was approximately 77%, and the plasma elimination half-life was about 10 hours. Urinary elimination of unchanged drug and metabolites accounted for approximately 40–50% of administered dose, with only about 4% excreted unchanged. These pharmacokinetic characteristics are relevant to lactation because a systemically absorbed, centrally active small-molecule medicine may enter human milk, while repeated dosing may create sustained maternal and milk exposure.pdf.hres

Toxicological profile

Mazindol has clinically important central nervous system, cardiovascular, psychiatric, and dependence-related toxicities. Its pharmacology creates predictable risks of sympathetic and monoaminergic overstimulation, particularly at higher doses, with prolonged administration, in patients with cardiovascular disease or psychiatric vulnerability, and during concomitant use of interacting drugs.pdf.hres

Commonly reported central nervous system adverse effects include nervousness, agitation, anxiety, restlessness, insomnia or other sleep disturbance, dizziness, headache, tremor, vertigo, and overstimulation. More serious reported neuropsychiatric reactions include depression, delirium, hallucinations, psychosis, seizures, and behavioural disturbance. Mazindol should therefore be avoided in patients with major psychiatric illness, marked agitation, eating disorders, or a history of substance misuse or medicine dependence.pdf.hres

Cardiovascular adverse effects include tachycardia, palpitations, precordial discomfort, and hypertension. Rare but serious reports include arrhythmia, angina, myocardial infarction, stroke, cardiac failure, cardiac arrest, and cerebrovascular events. The drug is contraindicated in patients with coronary artery disease, heart failure, clinically significant arrhythmias, cerebrovascular disease, pulmonary arterial hypertension, severe hypertension, or unstable/inadequately controlled hypertension. Blood pressure and resting heart rate require monitoring during therapy.pdf.hres

An especially important risk is pulmonary arterial hypertension. Centrally acting anorectic agents have historically been associated with this rare but severe, sometimes fatal condition. Although mazindol is described as a serotonin and norepinephrine reuptake inhibitor rather than a serotonin-releasing medicine, isolated cases of pulmonary arterial hypertension have been reported in treated patients. Exertional dyspnoea, unexplained chest pain or angina-like symptoms, syncope, and lower-limb oedema require prompt discontinuation and specialised cardiovascular assessment.pdf.hres

Mazindol can also contribute to serotonin toxicity when combined with serotonergic medicines. Co-administration with monoamine oxidase inhibitors is contraindicated because of the risk of severe hypertensive reactions. Concomitant use with serotonergic antidepressants, other centrally acting psychiatric medicines, St John’s wort, migraine medicines with serotonergic activity, or other centrally acting anorectic agents should be avoided or managed only under expert supervision, depending on the specific medicine and local regulatory guidance. Symptoms compatible with serotonin syndrome include agitation, confusion, hyperthermia, diaphoresis, tremor, hyperreflexia, incoordination, diarrhoea, vomiting, tachycardia, and labile blood pressure.pdf.hres

Prolonged use is associated with pharmacological tolerance, potential psychological dependence, and withdrawal phenomena. The risk of misuse is especially relevant because the medicine has stimulant-like central effects. In overdose, reported manifestations include nausea, vomiting, agitation, hyperactivity, confusion, tachycardia, cardiac arrhythmia, dyspnoea, seizures, coma, and potentially fatal outcomes, particularly in the context of co-exposure to alcohol or other medicines.pdf.hres

Lactation pharmacology and infant exposure

There are no adequate published human data defining mazindol concentrations in breast milk, milk-to-plasma ratios, relative infant dose, infant serum concentrations, or developmental outcomes in breastfed infants exposed through maternal treatment. Consequently, an evidence-based numerical estimate of infant exposure cannot be calculated.

This lack of data is clinically significant. Mazindol is a systemically absorbed, low-molecular-weight compound with a molecular weight of approximately 284.74 Da, and it has central nervous system activity. Medicines with low molecular weight, appreciable maternal plasma concentrations, lipophilicity, and incomplete plasma protein binding can diffuse into human milk. Mazindol’s reported 77% protein binding may limit the free fraction to some degree, but does not exclude clinically relevant transfer, especially during repeated dosing.kegg+2

The approximate 10-hour maternal plasma elimination half-life means that exposure is not necessarily confined to the immediate post-dose period. With repeated administration, maternal concentrations may persist across several feeding intervals. The breast is a dynamic compartment in equilibrium with maternal plasma rather than a static reservoir; nevertheless, ongoing maternal treatment can sustain infant exposure through repeated milk ingestion.pdf.hres+1

Potential pharmacological effects in a breastfed infant are not established by clinical case data, but are plausible from mazindol’s mechanism and toxicity profile. Particular concerns include:

  • Irritability, restlessness, excessive wakefulness, disturbed sleep, tremor, or unusual crying.
  • Poor feeding, reduced suck, vomiting, diarrhoea, constipation, or impaired weight gain.
  • Tachycardia, pallor, sweating, hypertension, or other autonomic effects.
  • Excessive drowsiness, altered alertness, or paradoxical behavioural effects.
  • Agitation, hyperexcitability, or rarely seizure-like activity in a vulnerable infant.
  • Accumulation risk in newborns, premature infants, and infants with renal, hepatic, neurological, or cardiovascular disease.

Infant vulnerability is highest during the neonatal period and in premature infants, in whom hepatic metabolism and renal drug elimination are immature. Central nervous system-active drugs account for a substantial proportion of reported adverse reactions in breastfed infants in general, and many reported events occur in infants younger than two months. These population-level observations do not establish mazindol-specific harm, but they strengthen the rationale for avoiding a poorly studied stimulant/anorectic in early lactation.tidsskriftet

Lactological safety assessment and clinical recommendations

Lactological safety assessment: Avoid during breastfeeding. Mazindol should not be used by breastfeeding women. The available product monograph explicitly lists lactation as a contraindication and states that mazindol should not be administered to lactating women. This position is justified by the absence of human milk and infant safety data, the medicine’s central monoaminergic activity, the possibility of cardiovascular and neuropsychiatric toxicity, its potential for dependence, and the non-urgent nature of pharmacological weight-loss treatment during lactation.pdf.hres

Mazindol should not be initiated to treat postpartum weight retention in a breastfeeding mother. Weight management during lactation should ordinarily prioritise gradual, nutritionally adequate weight loss; an appropriately balanced diet; physical activity compatible with postpartum recovery; sleep support; treatment of endocrine or metabolic contributors when indicated; and individualised medical assessment. Rapid or restrictive weight loss is undesirable during breastfeeding because it may compromise maternal well-being, nutritional intake, and the sustainability of lactation.

If a breastfeeding woman has taken mazindol, management should be individualised and should include prompt consultation with the prescriber, a clinical pharmacologist, a poison centre, or a specialist in lactation medicine. The clinician should establish:

  • The exact product, dose, formulation, frequency, duration of use, and timing of the last dose.
  • Whether exposure was a single accidental dose, intermittent use, or sustained treatment.
  • Co-exposures, especially antidepressants, MAO inhibitors, stimulants, decongestants, serotonergic medicines, alcohol, or other weight-loss products.
  • The infant’s age, prematurity, birth weight, feeding pattern, health status, and presence of hepatic, renal, neurological, or cardiac disease.
  • Any infant symptoms, including feeding difficulty, vomiting, altered sleep, unusual irritability, tremor, tachycardia, pallor, excessive sweating, breathing difficulty, or poor weight gain.
  • Maternal symptoms that may indicate cardiovascular toxicity, particularly palpitations, severe hypertension, chest pain, exertional dyspnoea, syncope, or peripheral oedema.

A validated mazindol-specific interval for interruption of breastfeeding cannot be stated because published milk elimination data are unavailable. Although pharmacokinetic principles sometimes use approximately five maternal elimination half-lives as a practical estimate for near-complete clearance from plasma and milk, this approach should not be applied rigidly in the absence of mazindol milk-concentration data, especially after repeated use or in the presence of infant vulnerability. Specialist case-specific advice is appropriate.tidsskriftet

Where clinically meaningful exposure has occurred, the infant should be observed for central nervous system and cardiovascular effects. Immediate paediatric evaluation is indicated if the infant develops poor feeding, persistent vomiting, unusual agitation, excessive somnolence, tremor, tachycardia, breathing difficulty, seizure-like activity, reduced urine output, or inadequate weight gain. Maternal cardiovascular assessment is also warranted where symptoms occur, given the potential for elevated blood pressure, tachyarrhythmia, and pulmonary arterial hypertension.pdf.hres

The appropriate clinical conclusion is therefore clear: mazindol is not compatible with routine breastfeeding, and safer non-pharmacological approaches should be preferred for postpartum weight management. If pharmacotherapy is genuinely necessary, the choice of an alternative requires individual assessment of the maternal indication, lactation evidence, infant age and health, and current regulatory guidance.

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.